Annick Desjardins: Clinical Trials

10 trials sponsored by Annick Desjardins, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated, 1 withdrawn. 7 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 4, Terminated 2, Withdrawn 1
Phase 23Completed 2, Terminated 1

Follow Annick Desjardins: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Sym004 - 18 mg/kg, Sym004 - 24 mg/kg - Malignant Glioma
Phase 2CompletedAnnick Desjardins432016-02-012020-08-05
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
CTO, Lomustine - Malignant Glioma (WHO Grade III or IV)
Phase 1TerminatedAnnick Desjardins92014-05-012016-08-04
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
CTO and Bevacizumab, CTO alone - Malignant Glioma (WHO Grade III or IV)
Phase 1TerminatedAnnick Desjardins172013-10-012016-02-19
Panitumumab and Irinotecan for Malignant Gliomas
Irinotecan, Panitumumab - Malignant Glioma of Brain
Phase 2TerminatedAnnick Desjardins162010-02-012013-09-04
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
AC480 - Glioma
Phase 1CompletedAnnick Desjardins52009-11-012014-01-29
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
bevacizumab and CPT-11 and Carboplatin - Malignant Glioma
Phase 2CompletedAnnick Desjardins1042009-09-012013-09-16
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
enzyme-inducing anti-epileptic drugs - Glioblastoma Multiforme, Gliosarcoma
Phase 1WithdrawnAnnick Desjardins2009-06-012012-11-21
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Vandetanib and Etoposide - Gliosarcoma, Glioblastoma
Phase 1CompletedAnnick Desjardins492008-02-012013-02-20
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Zactima, Gleevec, Hydroxyurea - Glioblastoma, Gliosarcoma
Phase 1CompletedAnnick Desjardins272007-11-012012-12-05
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Gleevec, RAD001, and Hydroxyurea - Glioblastoma, Gliosarcoma
Phase 1CompletedAnnick Desjardins782005-05-012013-02-20

Conditions studied

Glioma (9)  ·  Glioblastoma (7)  ·  Gliosarcoma (6)  ·  Brain Neoplasms (3)  ·  Astrocytoma (2)  ·  Lymphoma, Follicular (2)  ·  Oligodendroglioma (2)

Interventions

Bevacizumab (2)  ·  Hydroxyurea (2)  ·  Imatinib Mesylate (2)  ·  Irinotecan (2)  ·  vandetanib (2)  ·  Carboplatin (1)  ·  Etoposide (1)  ·  Everolimus (1)  ·  Lomustine (1)  ·  Panitumumab (1)  ·  etoposide phosphate (1)  ·  futuximab (1)

Countries

United States (10)

Results publications

PMID 21986722